Investor Presentaiton

Consolidated Income Statement Highlight Unit: THB, m Net sales Q1/2021 Q1/2022 %Chg. 119,346 138,887 16% Gross Profit Margin 19.9% 12.8% EBIT 12,708 6,134 -52% EBIT Margin 10.6% 4.4% EBITDA 19,486 13,615 -30% EBITDA Margin 16.3% 9.8% G/L on FV of Biological Assets (74) 1,098 1584% Financial Costs (4,098) (4,469) 9% Income Taxes Expense (2,117) (1,158) -45% Share in Profit of Associates 2,043 (336) -116% G/L on Sales of Invt. & Div. 0 1,595 100% NET PROFIT 6,945 2,842 -59% Net Profit Margin 5.8% 2.0% EPS (THB) # of capital shares Paid-Up Capital 0.85 0.34 7,988 7,937 8,611 8,611 P. 13

View entire presentation